Biopsy results explained

Active Surveillance After — a Prostate Biopsy

Being offered active surveillance is not being told that treatment is being withheld. It means your biopsy findings sit within a range where structured monitoring is as safe as immediate treatment — and avoids side effects that may never be needed.

Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed September 2026

Not inaction — Active surveillance is a clinical plan with a fixed schedule of tests and reviews — not a wait-and-see approach.
Criteria are specific — Eligibility depends on your grade group, PSA level, and how many cores were involved — all three together.
Monitoring follows a schedule — PSA tests, biopsies, and MRI scans happen at set intervals. You will know what is coming and when.
The plan can change — If the cancer upgrades, the plan moves to treatment. Detecting that change early is exactly what monitoring is for.

Book Free Consultation 1800 202 8726

4.8 · 800+ Google reviews · 15,000+ patients treated

17+

Cancer Specialists
on Panel

96.9%

Breast Cancer
Survival Rate*

15,000+

Patients
Treated

4.8★

Google Rating
(800+ reviews)

Active surveillance means structured monitoring instead of immediate treatment, for men whose biopsy findings meet specific low-risk criteria. It is not inaction. It follows a fixed schedule of PSA tests, repeat biopsies, and MRI scans. NCCN and ESMO list it as the preferred approach for qualifying patients.

What do the terms in your biopsy report and clinic letter mean?

Active surveillance: A structured monitoring plan chosen instead of immediate treatment. It includes scheduled PSA tests, biopsies, and scans, and is designed to move to treatment if the cancer changes — not to delay treatment indefinitely.
Watchful waiting: A different approach, often confused with active surveillance. Watchful waiting is less intensive and is usually offered when treatment is unlikely to be needed even if the disease progresses, often in older or less fit men. Your clinic letter will name which one applies to you.
PSA (Prostate-Specific Antigen): A protein made by prostate cells, measured by a blood test. Your PSA level at diagnosis, and how it changes over time during monitoring, is one of the main signals your team watches.
Grade Group: A scale that describes how the cancer cells look under the microscope — specifically how different they appear from normal cells. Lower grade groups suggest slower-growing cells. Your biopsy report assigns a grade group to each core sample taken.
Disease reclassification: When a repeat biopsy or MRI shows the cancer has a higher grade, or more core involvement, than the original biopsy found. Reclassification is what active surveillance is designed to detect early, and it usually leads to a change in plan.

Who qualifies for active surveillance?

Eligibility depends on three things together: the grade group in your biopsy report, your PSA level, and how many cores were involved and to what extent. A low grade group, a PSA within a lower-risk range, and limited core involvement are what point toward active surveillance being appropriate.

Your urologist will assess your results against published criteria — from NCCN, ESMO, or the EAU — and against your age and overall health. Because eligibility is not determined by any single number, the decision belongs with your urologist after reviewing the whole picture.

What does active surveillance monitoring involve?

PSA blood tests every few months in the early years, then at longer intervals once results are consistently stable
A repeat prostate biopsy within the first year or two, to confirm the original findings
Further biopsies at intervals your urologist sets — often every two to three years if earlier results are reassuring
An MRI scan, usually before or alongside a repeat biopsy, to look for changes a PSA test alone cannot detect
Regular clinic appointments to review results and discuss how you feel about continuing the plan

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile

Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile

Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile

Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile

Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile

Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile

Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile

Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile

Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile

Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile

Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile

Interventional Radiologist

Dr. Mohammed Imran

View Profile

Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile

Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

When does active surveillance change to treatment?

The most common reason the plan changes is reclassification — when a repeat biopsy shows a higher grade group than the first. A PSA that rises faster than expected between tests is another signal that prompts a closer look, usually with an earlier biopsy or scan.

Your urologist is watching the pattern over several readings, not reacting to any single result. If monitoring detects a meaningful change, the discussion about treatment happens then — with time to consider all options. You can also ask to move to treatment at any point, for any reason.

Questions families ask most about active surveillance

Does choosing active surveillance give the cancer a chance to spread?

This is the fear most families carry into that first appointment, and it deserves a direct answer. Active surveillance is offered because, for low-risk prostate cancer, the evidence does not show that immediate treatment produces better outcomes than structured monitoring. The cancer being monitored is, by definition, the kind the evidence classifies as slow-growing. The monitoring schedule is designed to detect any change before options narrow. Choosing active surveillance is not a gamble — it is the evidence-based recommendation for the right clinical picture.

What if I decide I want treatment now rather than continuing to monitor?

You can move to treatment at any point, for any reason — including anxiety about being on surveillance rather than a clinical change in results. Active surveillance is not a one-way door. If you decide you would rather treat, your urologist will discuss surgery and radiation and explain what each involves for your situation. Many men find anxiety settles once they see stable results over several monitoring cycles; others do not, and moving to treatment for quality-of-life reasons is a legitimate conversation your team will take seriously.

Is active surveillance available for all prostate cancer diagnoses?

No. It is appropriate for specific, lower-risk findings — typically a low grade group, limited biopsy core involvement, and a PSA within a lower-risk range. Higher-grade disease, or cancer that has spread beyond the prostate, is not managed this way. If your results do not meet the criteria, your urologist will explain why and what the recommended treatment approach is for your specific situation.

What happens if a repeat biopsy finds something worse than the first one?

A repeat biopsy showing a higher grade group — reclassification — means the plan needs to change. This is not a failure of active surveillance; it is the system detecting exactly what it was designed to detect. Treatment options are discussed and usually recommended at that point. Reclassification is found in a proportion of patients who remain on surveillance over a number of years, which is why the protocol includes repeat biopsies rather than relying on PSA alone.

Should I change my diet or take supplements during active surveillance?

There is no specific dietary prescription that active surveillance requires. General WCRF guidance on healthy weight, physical activity, and diet is reasonable to follow. No supplement, herbal preparation, or traditional medicine substitutes for scheduled monitoring. If you are taking anything — Ayurvedic preparations, vitamins, or anything else — tell your urologist before your next PSA test, because some preparations can affect PSA levels and alter the picture your team is tracking.

Did you know?

Major studies of active surveillance for low-risk prostate cancer show that most qualifying men do not need to move to treatment for many years, and some never do.

NCCN, ESMO, and the EAU all list active surveillance as the preferred first approach — not a fallback — for patients whose biopsy findings meet low-risk criteria.

Source: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer; ESMO Clinical Practice Guidelines: Prostate Cancer

Explore 114 more Waiting For and Understanding Your Report topics

Gleason & Prostate Biopsy Reporting

Cytology Reporting Systems

Grade, Differentiation & Mitotic Index

Margins, LVI and PNI

Reading Your Histopathology Report

Staging on a Biopsy Report

Waiting for Results

All Waiting For and Understanding Your Report →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726

Common questions

Frequently asked questions

What biopsy results make someone eligible for active surveillance?

Eligibility is not decided by one number. It depends on your grade group, your PSA level, and how many biopsy cores showed cancer and to what extent — all three together. The thresholds differ slightly between NCCN, ESMO, and EAU guidance, but all three require low-grade findings with limited involvement. Your urologist will tell you which criteria they are applying and where your specific results sit in relation to them.

How often will I need a repeat biopsy during active surveillance?

A first repeat biopsy is usually done within one to two years to confirm the initial findings. After that, the interval depends on what those early results show and which protocol your centre follows. MRI is increasingly used alongside or before repeat biopsies and can reduce how often a biopsy is needed in some cases. Your urologist will give you the specific schedule for your situation at your next appointment.

What does it mean if my PSA rises during active surveillance?

A single higher PSA reading does not automatically trigger a change of plan. Your urologist watches the pattern — how fast it is rising, over how many consecutive readings, and whether it is consistent. A rise that falls outside the expected pattern, or that continues over several tests, usually prompts an earlier biopsy or scan. One reading slightly above the previous result is typically repeated before any decision is made.

Can active surveillance monitoring be done locally, or do I need a specialist centre?

The tests active surveillance requires — PSA blood tests, MRI, and biopsy — are available at CION centres across Telangana and Andhra Pradesh. PET-CT, if needed as part of your assessment, is coordinated with partner imaging centres. Your urologist will tell you where each part of your monitoring schedule will take place and how it is coordinated.

Is it normal to feel anxious while on active surveillance?

Yes, and it is worth naming. Living with a cancer diagnosis while not treating immediately is not easy, even when it is the clinically right choice. Anxiety during active surveillance is common and does not mean the wrong decision was made. If anxiety is significantly affecting your daily life, tell your urologist or ask for a referral to a counsellor. If you would prefer treatment for quality-of-life reasons rather than a clinical change, that is a conversation your team will take seriously.

What should I ask at my next clinic appointment?

Ask four things: where your results sit relative to the eligibility criteria, what the monitoring schedule is and what each test is looking for, what finding would trigger a change of plan, and who to contact between appointments if something changes or you have a concern. Write the answers down — these appointments move quickly. It is entirely reasonable to ask for a written summary of your results and your monitoring schedule to take home.

Full index